# US 12,435,039 B2 · Activators of caspase-8/c-FLIPL dimerization and their use in cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,435,039 B2
- Document ID: US12435039B2
- Status: Granted
- Kind: B2
- Application number: 17/262,978
- Filed: 2019-07-16
- Published: 2022-11-17
- Granted: 2025-10-07
- Earliest claimed: 2018-07-25
- Assignees: Inna Lavrik
- Applicants: Inna Lavrik
- Inventors: Inna Lavrik; Laura Hillert; Nikita Ivanisenko; Vladimir Ivanisenko
- Web page: https://patentgrep.com/patent/US12435039B2

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 213/56: Amides
- C07C 311/16: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C12Q 1/37: involving peptidase or proteinase
- G01N 2333/96413: Cysteine endopeptidases (3.4.22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to activators of caspase-8/c-FLIPL dimerization and their use in enhancing the pro-apoptotic activity of the heterodimer and cancer therapy.

## Claims

### Claim 1

A compound, wherein said compound is
2-[[4-(4-pyridyl)benzoyl]amino]ethyl 3-(3-pyridylmethylsulfamoyl)benzoate according to formula III
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising an effective amount of the compound according to claim 1, together with a pharmaceutically acceptable carrier.